#Nvs stock free#

That year, the company increased the dividend payout by 3.61% YoY, from $3.08 to $3.19, representing a consistent growth in the past two years since 2019. The strong capital in FY2021 also allowed NVS to pay out $7.4B of dividends in FY2021.

#Nvs stock free#

In addition, the company has been generating robust Free Cash Flow growth since FY2008. It allowed the company to cash in their investment at an impeccable timing for maximum returns. The strategic move of selling Roche sales at a peak price of $388.99 points to the NVS management's highly astute business sense. The phenomenal debt repayment is mostly attributed to the capital received from the sale of 53.3M Roche shares at $20.7B in November 2021 and its robust Free Cash Flow at $13.3B for FY2021. The current level represents NVS's lowest amount of net debt since FY2010. In the latest earning call, NVS reported that it has paid off most of its net debt by $23.6B, to a net debt of $0.9B by FQ4'21. NVS Cash and Equivalents, Free Cash Flow and Long Term Debt With A Capable Management Team, NVS Achieved An Impressive $23.6B Of Debt Repayment Through Astute Business Sense If successfully divested, NVS is expected to gain another $25B of capital for its future pipeline, partnership, and M&A activities. On the other hand, Sandoz's sales have been flat in recent years, with NVS expected to either divest or spin off the segment by the end of FY2022. Nonetheless, NVS still reported a decent revenue of $51.6B in FY2021, representing a 6.1% YoY growth, mostly attributed to the increased volume from the Innovative Medicines. However, the therapeutic only delivered $1.3B of revenue in FY2021, compared to AbbVie's ( ABBV) Humira at a blockbuster $20.7B of revenue in the same year. NVS is also the pharmaceutical company that developed the world's most expensive therapeutic, Zolgensma, for the treatment of Spinal Muscular Atrophy, at a price tag of $2.1M. The debt repayment brought NVS's net debt level to a new low of $0.9B since FY2010. Kannan D/iStock Editorial via Getty Images Investment Thesisīy the end of FY2021, Novartis AG ( NYSE: NVS) had paid off a monumental $23.6B of debt through the sale of its 53.3M Roche shares at $20.7B and its robust Free Cash Flow of $13.3B.